Pipeline Data Slips to 2027, Sending Krystal Biotech Shares Lower
KRYS sits 57% above its 52-week low of $184.02.
Summary
Krystal Biotech disclosed that data readouts for its pipeline programs have been pushed to 2027, and the stock is trading lower on the news. That is a meaningful setback for a company whose commercial story is already solid — Q3 product revenue rose 30% to $127.3M with $63.1M in net income, and the board authorized up to $400M in buybacks. The delay matters because investors have been pricing in near-term catalysts beyond VYJUVEK, including the KB113 basal cell carcinoma work highlighted in the October 15 8-K showing regression in 83.1% of 83 assessed lesions in a Gorlin syndrome pilot. Pushing those readouts out a year removes the near-term news flow that supported the multiple.
At the time of this announcement, KRYS was trading at $289.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6B. The 52-week trading range was $184.02 to $382.54. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.